Clinically, when moderate-to-severe psoriasis patients were treated with systemic anti-IL-17A monoclonal antibody (secukinumab) administration for 52 weeks and then stopped the treatment, 16.0% of them maintained response after treatment withdrawal over the next 52 weeks without need for retreatment (12, 13). This evidence concerns the gene IL17A and psoriasis.